Key Findings from the AACR Abstract and Poster

• Meaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions
• 177Lu-RAD202 was generally well tolerated in the first three treated patients, with predominantly Grade 1–2 treatment-emergent adverse events
• No dose-limiting toxicities or treatment discontinuations due to adverse events were observed
• Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation

Poster Presentation Details

• Title: A First-in-Class HER2-Targeted Radiopharmaceutical Therapy: Initial Findings from the Phase 0/1 HEAT Trial of 177Lu-RAD202 in HER2+ Advanced Solid Tumors
• Abstract Number: CT046
• Presenter: Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics
• Session: Poster Session
• Dates: April 20, 2026 at 9:00 AM PT

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.